|
Gene: TLN2 |
Gene summary for TLN2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | TLN2 | Gene ID | 83660 |
Gene name | talin 2 | |
Gene Alias | ILWEQ | |
Cytomap | 15q22.2 | |
Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q9Y4G6 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83660 | TLN2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 1.60e-22 | -6.43e-01 | 0.0155 |
83660 | TLN2 | HTA11_347_2000001011 | Human | Colorectum | AD | 2.13e-09 | 6.41e-01 | -0.1954 |
83660 | TLN2 | HTA11_696_2000001011 | Human | Colorectum | AD | 5.19e-03 | -3.13e-01 | -0.1464 |
83660 | TLN2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.34e-16 | -7.11e-01 | 0.096 |
83660 | TLN2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 3.06e-04 | -8.71e-01 | 0.0451 |
83660 | TLN2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 2.82e-07 | -6.66e-01 | 0.0528 |
83660 | TLN2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.27e-09 | -4.52e-01 | 0.0674 |
83660 | TLN2 | HTA11_6818_2000001011 | Human | Colorectum | AD | 7.06e-04 | -4.27e-01 | 0.0112 |
83660 | TLN2 | HTA11_6818_2000001021 | Human | Colorectum | AD | 5.63e-12 | -6.49e-01 | 0.0588 |
83660 | TLN2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 8.01e-39 | -8.26e-01 | 0.294 |
83660 | TLN2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.50e-55 | -1.06e+00 | 0.3859 |
83660 | TLN2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 1.07e-17 | -1.02e+00 | 0.2585 |
83660 | TLN2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.28e-51 | -9.32e-01 | 0.3005 |
83660 | TLN2 | F007 | Human | Colorectum | FAP | 8.09e-05 | -3.94e-01 | 0.1176 |
83660 | TLN2 | A002-C-010 | Human | Colorectum | FAP | 3.77e-04 | -3.49e-01 | 0.242 |
83660 | TLN2 | A001-C-207 | Human | Colorectum | FAP | 1.18e-06 | -3.72e-01 | 0.1278 |
83660 | TLN2 | A015-C-203 | Human | Colorectum | FAP | 3.71e-38 | -6.70e-01 | -0.1294 |
83660 | TLN2 | A015-C-204 | Human | Colorectum | FAP | 7.06e-13 | -5.73e-01 | -0.0228 |
83660 | TLN2 | A014-C-040 | Human | Colorectum | FAP | 2.23e-11 | -7.55e-01 | -0.1184 |
83660 | TLN2 | A002-C-201 | Human | Colorectum | FAP | 1.54e-23 | -6.07e-01 | 0.0324 |
Page: 1 2 3 4 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000704315 | Endometrium | EEC | cell-cell junction assembly | 31/2168 | 146/18723 | 5.74e-04 | 5.72e-03 | 31 |
GO:003432912 | Lung | AIS | cell junction assembly | 84/1849 | 420/18723 | 2.16e-10 | 5.71e-08 | 84 |
GO:004521613 | Lung | AIS | cell-cell junction organization | 41/1849 | 200/18723 | 4.66e-06 | 2.31e-04 | 41 |
GO:000704313 | Lung | AIS | cell-cell junction assembly | 31/1849 | 146/18723 | 3.18e-05 | 1.01e-03 | 31 |
GO:0034329111 | Thyroid | PTC | cell junction assembly | 180/5968 | 420/18723 | 1.17e-06 | 1.69e-05 | 180 |
GO:0045216111 | Thyroid | PTC | cell-cell junction organization | 93/5968 | 200/18723 | 1.01e-05 | 1.12e-04 | 93 |
GO:0007043111 | Thyroid | PTC | cell-cell junction assembly | 64/5968 | 146/18723 | 1.56e-03 | 8.63e-03 | 64 |
GO:003432924 | Thyroid | ATC | cell junction assembly | 187/6293 | 420/18723 | 1.71e-06 | 2.08e-05 | 187 |
GO:004521629 | Thyroid | ATC | cell-cell junction organization | 99/6293 | 200/18723 | 2.26e-06 | 2.68e-05 | 99 |
GO:000704324 | Thyroid | ATC | cell-cell junction assembly | 70/6293 | 146/18723 | 2.24e-04 | 1.46e-03 | 70 |
Page: 1 2 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa04015 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa04510 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa05166 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051311 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa040151 | Colorectum | AD | Rap1 signaling pathway | 71/2092 | 210/8465 | 1.72e-03 | 9.68e-03 | 6.18e-03 | 71 |
hsa045101 | Colorectum | AD | Focal adhesion | 67/2092 | 203/8465 | 4.40e-03 | 2.17e-02 | 1.38e-02 | 67 |
hsa051661 | Colorectum | AD | Human T-cell leukemia virus 1 infection | 72/2092 | 222/8465 | 5.24e-03 | 2.44e-02 | 1.55e-02 | 72 |
hsa051312 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa040152 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa051313 | Colorectum | SER | Shigellosis | 87/1580 | 247/8465 | 3.07e-10 | 7.27e-09 | 5.28e-09 | 87 |
hsa040153 | Colorectum | SER | Rap1 signaling pathway | 54/1580 | 210/8465 | 6.55e-03 | 3.68e-02 | 2.67e-02 | 54 |
hsa051314 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa040154 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa051662 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
hsa051315 | Colorectum | MSS | Shigellosis | 94/1875 | 247/8465 | 6.82e-09 | 1.34e-07 | 8.23e-08 | 94 |
hsa040155 | Colorectum | MSS | Rap1 signaling pathway | 66/1875 | 210/8465 | 1.03e-03 | 5.94e-03 | 3.64e-03 | 66 |
hsa051663 | Colorectum | MSS | Human T-cell leukemia virus 1 infection | 68/1875 | 222/8465 | 1.84e-03 | 9.61e-03 | 5.89e-03 | 68 |
hsa051318 | Colorectum | FAP | Shigellosis | 76/1404 | 247/8465 | 1.57e-08 | 5.84e-07 | 3.55e-07 | 76 |
hsa045102 | Colorectum | FAP | Focal adhesion | 61/1404 | 203/8465 | 1.03e-06 | 2.15e-05 | 1.31e-05 | 61 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TLN2 | SNV | Missense_Mutation | rs754986736 | c.1454N>A | p.Arg485Gln | p.R485Q | Q9Y4G6 | protein_coding | tolerated(0.4) | possibly_damaging(0.716) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
TLN2 | SNV | Missense_Mutation | novel | c.5716G>A | p.Ala1906Thr | p.A1906T | Q9Y4G6 | protein_coding | tolerated(0.19) | benign(0.155) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TLN2 | SNV | Missense_Mutation | c.7362N>T | p.Met2454Ile | p.M2454I | Q9Y4G6 | protein_coding | tolerated(0.07) | probably_damaging(0.992) | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
TLN2 | SNV | Missense_Mutation | novel | c.3484G>A | p.Glu1162Lys | p.E1162K | Q9Y4G6 | protein_coding | tolerated(0.67) | benign(0.269) | TCGA-BH-A0HF-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
TLN2 | SNV | Missense_Mutation | c.5096N>T | p.Ala1699Val | p.A1699V | Q9Y4G6 | protein_coding | tolerated(0.1) | benign(0.354) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TLN2 | SNV | Missense_Mutation | c.3785C>T | p.Thr1262Ile | p.T1262I | Q9Y4G6 | protein_coding | tolerated(0.25) | benign(0.11) | TCGA-C8-A12Q-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | |
TLN2 | SNV | Missense_Mutation | novel | c.514G>A | p.Asp172Asn | p.D172N | Q9Y4G6 | protein_coding | deleterious(0) | benign(0.263) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TLN2 | SNV | Missense_Mutation | c.4714G>A | p.Glu1572Lys | p.E1572K | Q9Y4G6 | protein_coding | tolerated(0.17) | possibly_damaging(0.593) | TCGA-C8-A26Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TLN2 | SNV | Missense_Mutation | c.626N>A | p.Arg209Lys | p.R209K | Q9Y4G6 | protein_coding | tolerated(0.1) | probably_damaging(0.993) | TCGA-D8-A1J8-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | nolvadex | SD | |
TLN2 | SNV | Missense_Mutation | novel | c.6479N>G | p.Val2160Gly | p.V2160G | Q9Y4G6 | protein_coding | deleterious(0.03) | benign(0.088) | TCGA-D8-A1JD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |